Comparative Pharmacology
Head-to-head clinical analysis: CEFPIRAMIDE SODIUM versus CEFTAZIDIME SODIUM IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFPIRAMIDE SODIUM versus CEFTAZIDIME SODIUM IN PLASTIC CONTAINER.
CEFPIRAMIDE SODIUM vs CEFTAZIDIME SODIUM IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefpiramide sodium is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Ceftazidime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP3, inhibiting transpeptidase activity and disrupting peptidoglycan cross-linking, leading to cell lysis and death.
1-2 g IV every 12 hours; maximum 8 g/day
1-2 g IV every 8 hours for pseudomonal infections; 500 mg to 1 g IV every 8-12 hours for uncomplicated UTIs.
None Documented
None Documented
4-5 hours in normal renal function; prolonged to 12-20 hours in severe renal impairment (CrCl < 20 mL/min)
1.5–2.0 hours in normal renal function; prolonged to 15–30 hours in ESRD.
Renal: 80-90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: 10-20%
Primarily renal (80–90% unchanged via glomerular filtration); biliary/fecal <1%.
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic